Q32 Bio’s stock crash­es af­ter atopic der­mati­tis fail, alope­cia tri­al sna­fu

Af­ter a mid-stage fail­ure in atopic der­mati­tis, Q32 Bio plans to take be­m­pik­ibart for­ward in alope­cia in­stead, de­spite a tri­al in that in­di­ca­tion al­so com­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER